Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
31.44 USD | -0.74% | +6.64% | +41.40% |
Financials (USD)
Sales 2024 * | 42.22M | Sales 2025 * | 114M | Capitalization | 1.78B |
---|---|---|---|---|---|
Net income 2024 * | -318M | Net income 2025 * | -361M | EV / Sales 2024 * | 40.5 x |
Net cash position 2024 * | 68.82M | Net Debt 2025 * | 36.47M | EV / Sales 2025 * | 16 x |
P/E ratio 2024 * |
-5.78
x | P/E ratio 2025 * |
-5.38
x | Employees | 385 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 76.35% |
Latest transcript on Agios Pharmaceuticals, Inc.
1 week | +7.61% | ||
Current month | +8.31% | ||
1 month | +6.70% | ||
3 months | +35.23% | ||
6 months | +56.94% | ||
Current year | +42.21% |
Managers | Title | Age | Since |
---|---|---|---|
Brian Goff
CEO | Chief Executive Officer | 55 | 22-08-07 |
Cecilia Jones
DFI | Director of Finance/CFO | 49 | 22-09-25 |
Jacqualyn Fouse
CHM | Chairman | 62 | 17-12-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jeffrey Capello
BRD | Director/Board Member | 69 | 23-05-31 |
Director/Board Member | 64 | 14-12-08 | |
May Kin Ho
BRD | Director/Board Member | 71 | 15-06-22 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.52% | 1 M€ | 0.00% | - | |
0.16% | 0 M€ | 0.00% | - | |
0.14% | 0 M€ | 0.00% | - | |
0.06% | 509 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 31.45 | -0.69% | 131 711 |
24-04-25 | 31.67 | 0.00% | 721,957 |
24-04-24 | 31.67 | -0.44% | 643,302 |
24-04-23 | 31.81 | +5.30% | 1,225,395 |
24-04-22 | 30.21 | +2.30% | 861,755 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+42.21% | 1.78B | |
-2.26% | 103B | |
+1.41% | 95.71B | |
+0.55% | 22.02B | |
-17.84% | 20.9B | |
-10.09% | 17.85B | |
-42.83% | 16.21B | |
-17.63% | 15.52B | |
+4.55% | 13.86B | |
+32.11% | 12.04B |
- Stock Market
- Equities
- AGIO Stock